Zika vaccine race spurred by crisis and profit potential



The race to find protection against the Zika virus is fuelled by something often missing from tropical disease research: the potential for big profit.
The prospect of a blockbuster vaccine against a mosquito-borne virus has accelerated the pace of development and attracted the interest of big drugmakers, including Sanofi SA, GlaxoSmithKline Plc and Takeda Pharmaceuticals.
Although Zika infections are mild or asymptomatic in most people, demand for a vaccine is expected to be strong because it can cause devastating birth defects, pharmaceutical executives and disease experts said.
The most... read more

 
4 October 2016 in Business, Views: 48
Source: Reuters
Share:
  •  





    News Widget for Webmasters



    Bring Eugene's son back home immediately

    Realtime News

     

    «
    »
    Mo Tu We Th Fr Sa Su
          1 2 3 4
    5 6 7 8 9 10 11
    12 13 14 15 16 17 18
    19 20 21 22 23 24 25
    26 27 28 29 30 31